" class="no-js "lang="en-US"> Restore Medical Announces Success in Systolic Heart Failure
Thursday, March 23, 2023

Breaking News

Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million Medtronic to Boost AI Innovation with New Platform Introduction Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease
Restore Medical Announces Successful First-In-Human Preliminary Results of Its CONTRABAND™ System for Symptomatic Systolic Heart Failure Patients | MTA

March 7 2023

Restore Medical Announces Successful First-In-Human Preliminary Results of Its CONTRABAND™ System for Symptomatic Systolic Heart Failure Patients

Restore Medical, a privately held medical device company, has successfully completed enrollment of the First In Human clinical study with its CONTRABAND™ device for Symptomatic Systolic Heart Failure Patients. The world’s first and only Pulmonary Artery Banding (PAB) transcatheter implant by Restore Medical is designed to treat heart failure with reduced ejection fraction (HFrEF) and improve the quality of life for heart failure patients.

The feasibility, multi-center, prospective study enrolled 15 patients who were already on maximally tolerated guideline directed medical therapy (GDMT) across 5 hospitals in Europe. All treated patients experienced symptom improvement, leading to the expansion of the clinical program.

The six-month and one-year results of the study demonstrated that the CONTRABAND™ device improved the quality of life of the treated patients, as demonstrated by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and six-minute walk test (6MWT), and led to a reduction in the New York Heart Association (NYHA) heart class and improvement of left ventricle ejection fraction (LVEF). The implantation procedure was safe for all participants, with excellent long-term right ventricular safety.

  1. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer

    News

     Read more
  2. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

    Diseases

     Read more
  3. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

    Drug Development

     Read more
  4. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

    News

     Read more
  5. Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President

    Appointments

     Read more
More On